文献速递药物不良反应与药物警戒药物相互作用治疗药物监测与药物基因组学

达托霉素治疗期间肌酸磷酸激酶升高的影响因素:机器学习与传统方法联合分析

Factors affecting creatine phosphokinase elevation during daptomycin therapy using a combination of machine learning and conventional methods.
PubMed 文献 · Br J Clin Pharmacol · 2021-09-28

本研究基于日本电子病历数据库开展回顾性队列研究,纳入706例接受达托霉素治疗的患者,采用多元逻辑回归与决策树分析识别CPK升高的独立因素。结果显示基线CPK值和联用亲脂性他汀是共同独立因素,亲水性他汀则否;联用亲脂性他汀且基线CPK高的患者属高危组,需频繁监测CPK。

要点

  • 基线CPK值和联用亲脂性他汀是达托霉素相关CPK升高的独立因素。
  • 联用亲水性他汀未显示为CPK升高的独立因素。
  • 联用亲脂性他汀且基线CPK高的患者为高危组,需频繁监测CPK。

核心结论

  • 基线CPK值和联用亲脂性他汀是达托霉素治疗期间CPK升高的独立影响因素。
  • 联用亲水性他汀不是CPK升高的独立影响因素。
  • 联用亲脂性他汀且基线CPK高的患者属于CPK升高高危组,建议频繁监测CPK。

研究设计与样本

  • 基于日本电子病历数据库的回顾性观察性队列研究。

主要发现

  • 706例中CPK升高>200 IU/L且较基线升高>2倍者83例(11.8%)。
  • 706例中CPK升高>1000 IU/L者17例(2.41%)。
  • 多元逻辑回归显示基线CPK值和联用亲脂性他汀是各CPK升高定义的共同独立因素,联用亲水性他汀则不是。
  • 决策树分析将联用亲脂性他汀且基线CPK高的患者归为高危组。

关键数值与推荐

  • 肌骨毒性定义1:CPK值较基线升高超过2倍且>200 IU/L。
  • 肌骨毒性定义2:CPK值>1000 IU/L。

临床怎么用

  • 对接受达托霉素治疗的患者,应关注基线CPK值及是否联用亲脂性他汀。
  • 联用亲脂性他汀且基线CPK高的患者建议频繁监测CPK。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Musculoskeletal toxicity is a typical side effect of daptomycin (DAP). However, the risk factors have not been well established. Here, we aimed to identify independent factors affecting DAP-induced musculoskeletal toxicity using a combination of machine learning and conventional statistical methods. METHODS: A population-based, retrospective, observational cohort study was conducted using the Japanese electronic medical record database. Patients who received DAP between October 2011 and December 2020 were enrolled. Two definitions of musculoskeletal toxicity were employed: (1) elevation of creatine phosphokinase (CPK) value more than twice from baseline and >200 IU/L, and (2) >1000 IU/L. First, multiple logistic regression analyses (a conventional statistical method) were performed to identify independent factors affecting CPK elevation. Then, decision tree analyses, a machine learning method, were performed to detect combinations of factors that change CPK elevation risk. RESULTS: Of the 2970 patients who received DAP, 706 were included. Elevation of CPK values >200 IU/L and >1000 IU/L occurred in 83 (11.8%) and 17 (2.41%) patients, respectively. In multiple logistic regression analysis, baseline CPK value and concomitant use of hydrophobic statins were commonly extracted as independent factors affecting each CPK elevation, but concomitant use of hydrophilic statins was not. In decision tree analysis, patients who received hydrophobic statins and had high baseline CPK values were classified into the high-risk group. CONCLUSION: Our novel approach revealed new risk factors for CPK elevation. Our findings suggest that high-risk patients require frequent CPK monitoring.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Imai S, Kashiwagi H, Sato Y, et al. Factors affecting creatine phosphokinase elevation during daptomycin therapy using a combination of machine learning and conventional methods. Br J Clin Pharmacol. 2021. PMID: 34436795. doi:10.1111/bcp.15063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。